Drug Profile
Research programme: cancer therapeutics - Regen BioPharma
Alternative Names: Checkpoint inhibitor pill - Regen BioPharma; dCellVax™; DiffronC; IDO-silenced cancer immunotherapeutic - Regen Biopharma; IDO-silenced dendritic cell vaccine - Regen Biopharma; NR2F6 inhibitors - Regen BioPharma; NR2F6 T cell immunotherapy; NR2F6-silenced cancer therapeutics - Regen BioPharma; RGBP-248; tCellVax; ucVAX; Universal donor cell therapy - Regen BioPharmaLatest Information Update: 28 Mar 2024
Price :
$50
*
At a glance
- Originator University of Western Ontario
- Developer Regen BioPharma; University of Lausanne; University of Western Ontario
- Class Cancer vaccines; Dendritic cell vaccines; Gene therapies; Small interfering RNA; Small molecules
- Mechanism of Action Dendritic cell modulators; Gene silencing; Gene transference; Immunostimulants; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Myelodysplastic syndromes
- No development reported Breast cancer; Colorectal cancer; Leukaemia; Liver cancer
Most Recent Events
- 28 Mar 2024 No recent reports of development identified for preclinical development in Breast-cancer in USA
- 20 Jan 2023 Regen BioPharm files a provisional patent protection covering the use of survivin-engineered dendritic cells and exosomes for stimulation of anti-cancer immunity
- 19 Sep 2022 Regen BioPharma files a provisional patent application for dual checkpoint inhibitor aptamer based therapeutics in the US